XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

A research team led by Mount Sinai School of Medicine has identified the mechanism behind a single gene linked to the causes of both Alzheimer's disease and Type 2 diabetes.

KeyVive, Inc., a healthcare technology company that uses social media and self management tools to help individuals with chronic illnesses, is dialing up a ground-breaking, HIPAA compliant mHealth technology for people not only affected by diabetes, but also with other diseases.

Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs. A majority of people with Type 1 diabetes who were tested in the study were found to have the newly-identified cellular/molecular defect, and the researchers were able to successfully correct the defect in-vitro.

The Food and Drug Administration and European regulators said they were taking action on Avandia, made by GlaxoSmithKline PLC, because of data tying it to increased risk of heart attacks.